Insider Sheds Nearly 53,000 Shares of Consumer Health Stock, Valued at Almost $900,000
Key Points
Frederick Munsch sold 52,900 shares on August 10, 2026, for a total estimated value of ~$888,000.
The transaction represents a 54% reduction in the insider's direct equity holdings.
The disposal was executed as a direct sale of common stock at a weighted average price of $16.78 per share.
This liquidation occurred following a 12-month period in which the stock returned 23% as of the August 10, 2026 transaction date.
Frederick Munsch, SVP, Controller and CAO of Bausch + Lomb Corporation (NYSE:BLCO), sold 52,900 shares of common stock on Aug. 10, 2026, according to a recently disclosed SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | ~$887,662 |
| Shares sold | 52,900 |
| Post-transaction shares (directly held) | 45,831 |
| Post-transaction value | $771,335.73 |
Transaction value based on SEC Form 4 weighted average sale price ($16.78); post-transaction value based on Aug. 10, 2026, market close ($16.83).
Company snapshot
- Sector: Healthcare
- Industry: Medical - Instruments & Supplies
- Market Cap: $6.0 billion
- Employees: 13,000
Bausch + Lomb Corporation is a global eye health company structured across segments, including Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The firm provides a portfolio ranging from contact lenses and care products to nutritional supplements and surgical equipment.
Key questions
- What was the magnitude of the transaction relative to the insider's total equity stake?
Frederick Munsch liquidated 54% of his direct common stock position, selling 52,900 shares and retaining 45,831 shares after the transaction. - How did the transaction price compare to recent market levels?
The sale was completed at a weighted average price of $16.78, while the stock was priced at $16.87 as of the Aug. 11, 2026, market close. - What is the current financial profile of the firm?
Bausch + Lomb Corporation reported trailing twelve-month revenue of $5.3 billion and a net income loss of -$171.0 million, according to the latest available data.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-11) | $16.87 |
| Market Capitalization | $6.0 billion |
| Revenue (TTM) | $5.3 billion |
| Net Income (TTM) | -$171.0 million |
Company Snapshot
- Bausch + Lomb operates as a diversified global eye health company with three primary business segments: Vision Care/Consumer Health, which generates revenue through contact lenses and care products; Ophthalmic Pharmaceuticals, which focuses on prescription eye medications; and Surgical, which provides surgical instruments and devices for ophthalmic procedures.
- The company's business model centers on delivering comprehensive eye health solutions across the consumer, pharmaceutical, and surgical markets, generating revenue through product sales, licensing arrangements, and service offerings to ophthalmologists, optometrists, and end consumers.
- Bausch + Lomb serves a diverse customer base, including eye care professionals, healthcare institutions, and consumers globally, with particular strength in the contact lens market and established relationships with leading healthcare providers and retail distribution channels.
Bausch + Lomb is a leading global eye health company with approximately 13,000 employees and TTM revenue of $5.3 billion, positioning it as a significant player in the medical instruments and supplies sector. The company maintains a diversified portfolio spanning consumer vision care, pharmaceutical treatments, and surgical solutions, enabling it to capture value across multiple segments of the eye health market. With a market capitalization of $6.0 billion and a one-year share price appreciation of 23.39%, the company demonstrates investor confidence in its market positioning and operational trajectory.
What this transaction means for investors
As many investors know, insider transactions come in many differing flavors. Many of them are triggered by mundane events unrelated to a stock’s near-term prospects. Yet insider transactions can serve as a starting point for investors to dig deeper and determine whether a stock is right for them.
With that in mind, let’s turn directly to Baush + Lomb (BLCO). The company’s stock has been stuck in neutral for about four years. During this time, the stock has delivered a total return of -7%, amounting to a compound annual growth rate (CAGR) of -1.7%. That compares very unfavorably to the S&P 500, which has generated a total return of 97.8% over the same period, with a CAGR of 17.3%.
One area that has plagued BLCO is its high debt load. The company’s net debt stands at $4.7 billion, up from $2.0 billion in 2022. Much of this debt is the result of how the company was spun off years ago. Nevertheless, its high debt load can act as an anchor, forcing the company to service it and refinance at potentially higher rates down the road.
As for positives, the company’s overall operating margin has bounced back. Operating margin increased to 7.6%, its highest level in more than four years. This indicates that the company is successfully navigating current market conditions and delivering increasing profits.
To sum up, BLCO is a stock that has underperformed for years and is weighed down with more than $4 billion in debt. While its overall profitability is growing, its balance sheet may discourage some investors from considering the stock.
Jake Lerch has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.